PF-06835375 for Thrombocytopenic Purpura
Study Summary
This trial is testing a new drug for adults with primary immune thrombocytopenia, a condition where the body doesn't produce enough platelets. The drug will be given as injections, and the trial will assess the safety and effectiveness of the drug.
- Idiopathic Thrombocytopenic Purpura (ITP)
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Has the FDA cleared PF-06835375 for use?
"Although there is some evidence that PF-06835375 is safe, as it is only a Phase 2 trial, there is no data yet to support its efficacy."
Could you tell me if this research is only meant for people over 60 years old?
"The standards to be included in this particular study are that patients are aged 18-70. However, if a patient is under 18 there are 26 other trials they could be a part of and if a patient is over 65 there are 112 trials."
Is this research project also taking place in other countries besides the United States?
"This study is recruiting patients at Mayo Clinic in Florida in Jacksonville, Unity Health Toronto, St. Michael's Hospital in Toronto, Hematology Oncology Associates of Rockland in Nyack, and nine other locations."
Are individuals needed for this research project?
"The information available on clinicaltrials.gov does suggest that this clinical trial is presently recruiting patients. This clinical trial was initially posted on 2/2/2022 and was most recently updated on 10/26/2022. The clinical trial is recruiting for 40 participants at 9 locations."
Who meets the screening criteria to participate in this trial?
"The recruitment goal for this clinical trial is 40 patients that have thrombocytopenia and are between 18 and 70 years old. In order to be eligible, potential participants must also meet the following requirements: A formal diagnosis of Primary ITP, an ongoing ITP with platelet counts lower than 50 x 109/L, [No severe bleeding in the month prior or during screening], AND either 3 to 12 months of Persistent ITP or Chronic ITP for over 12 months."